Exercise-stimulated Muscle Glucose Uptake in Upper Body Obesity

Upper Body Obesity Clinical Trial

Official title:

Exercise-stimulated Muscle Glucose Uptake in Upper Body Obesity

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04532814
• Other study ID #: 20-002949
• Secondary ID: R01DK045343
• Status: Recruiting
• Phase: N/A
• Start date: November 6, 2020
• Est. completion date: July 2025

Study information

• Verified date: March 2024
• Source: Mayo Clinic
• Contact: Pamela Reich
• Phone: 507-255-6062
• Email: reich.Pamela[@]mayo.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to provide the first integrated examination of the interaction between muscle insulin action and exercise-stimulated muscle glucose uptake in obesity from the whole body to the cellular/molecular level.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 48
• Est. completion date: July 2025
• Est. primary completion date: July 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

For the exercise studies of leg glucose uptake - "insulin sensitive" group:

• Sedentary, normal weight, premenopausal women.

• Sedentary, age-matched normal weight men.

• Weight stable for two (2) months prior to study.

• Willing to provide written, informed consent.

• For the exercise studies of leg glucose uptake - "insulin resistant" group:

For the exercise studies of leg glucose uptake - "insulin resistant" group:

• Upper body obese (UBO) premenopausal women.

• Age-matched upper body obese (UBO) men.

• Weight stable for two (2) months prior to study.

• Willing to provide written, informed consent.

Exclusion Criteria:

• Age < 18 or > 55 years (premenopausal women and age-matched men).

• Use of glucose-lowering agents.

• For female subjects: positive pregnancy test at the time of enrollment or study

• History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy.

• Active systemic illness or malignancy.

• Symptomatic macrovascular or microvascular disease.

Related Conditions & MeSH terms

• Obesity
• Upper Body Obesity

Intervention

Other:
• Exercise
Cycling 60% VO2 max

Locations

Country	Name	City	State
United States	Mayo Clinic in Rochester	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Mayo Clinic	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Skeletal muscle glucose uptake	Is exercise induced skeletal muscle glucose uptake different in obese compared to lean adults	1 hour